Biotechnology company Revance Therapeutics Inc (Nasdaq:RVNC) stated on Tuesday that it plans to start an underwritten public offering of its common stock.
Net proceeds from the planned offering of common stock may be used by the company to continue to fund the commercialisation of DAXI, working capital, research and development as well as general corporate purposes.
Subject to market and other conditions, the company said there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cowen, Piper Jaffray & Co and Stifel are acting as book-running managers for the proposed offering.
Revance Therapeutics develops next-generation neuromodulators for treating aesthetic and therapeutic conditions.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA